These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 25528530)

  • 1. Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis.
    Senoo K; Lane DA; Lip GY
    Int J Cardiol; 2015 Feb; 181():247-54. PubMed ID: 25528530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS
    Katz DF; Maddox TM; Turakhia M; Gehi A; O'Brien EC; Lubitz SA; Turchin A; Doros G; Lei L; Varosy P; Marzec L; Hsu JC
    Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score.
    Lip GY; Skjøth F; Rasmussen LH; Larsen TB
    J Am Coll Cardiol; 2015 Apr; 65(14):1385-94. PubMed ID: 25770314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
    Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
    Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHA
    Kim TH; Yang PS; Kim D; Yu HT; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
    Stroke; 2017 Nov; 48(11):2984-2990. PubMed ID: 28939672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?
    Chao TF; Liu CJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chen TJ; Lip GY; Chen SA
    J Am Coll Cardiol; 2015 Feb; 65(7):635-42. PubMed ID: 25677422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler M; Day JD; Weiss JP; Osborn JS; Muhlestein JB; Anderson JL; Mallender C; Bunch TJ
    Heart Rhythm; 2015 Apr; 12(4):681-6. PubMed ID: 25546809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of renal function deterioration on adverse events during anticoagulation therapy using non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    Miyamoto K; Aiba T; Arihiro S; Watanabe M; Kokubo Y; Ishibashi K; Hirose S; Wada M; Nakajima I; Okamura H; Noda T; Nagatsuka K; Noguchi T; Anzai T; Yasuda S; Ogawa H; Kamakura S; Shimizu W; Miyamoto Y; Toyoda K; Kusano K
    Heart Vessels; 2016 Aug; 31(8):1327-36. PubMed ID: 26276272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients.
    Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA
    Europace; 2014 Feb; 16(2):195-201. PubMed ID: 24036378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
    Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
    Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHA
    Kim TH; Yang PS; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
    Stroke; 2017 Jun; 48(6):1524-1530. PubMed ID: 28455320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.
    Zhu WG; Xiong QM; Hong K
    Tex Heart Inst J; 2015 Feb; 42(1):6-15. PubMed ID: 25873792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between CHADS2 and CHA2DS2-VASc score for risk stratification of ischemic stroke in Japanese patients with non-valvular paroxysmal atrial fibrillation not receiving anticoagulant therapy.
    Komatsu T; Sato Y; Ozawa M; Kunugita F; Yoshizawa R; Morino Y; Nakamura M
    Int Heart J; 2014; 55(2):119-25. PubMed ID: 24632957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.
    Melgaard L; Gorst-Rasmussen A; Lane DA; Rasmussen LH; Larsen TB; Lip GY
    JAMA; 2015 Sep; 314(10):1030-8. PubMed ID: 26318604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukoaraiosis and stroke recurrence risk in patients with and without atrial fibrillation.
    Ntaios G; Lip GY; Lambrou D; Papavasileiou V; Manios E; Milionis H; Spengos K; Makaritsis K; Vemmos K
    Neurology; 2015 Mar; 84(12):1213-9. PubMed ID: 25695964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation.
    Tu HT; Campbell BC; Meretoja A; Churilov L; Lees KR; Donnan GA; Davis SM
    Cerebrovasc Dis; 2013; 36(4):273-80. PubMed ID: 24135809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of CHA
    van Doorn S; Rutten FH; O'Flynn CM; Oudega R; Hoes AW; Moons KGM; Geersing GJ
    Int J Cardiol; 2018 Dec; 273():123-129. PubMed ID: 30224261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry.
    Kornej J; Hindricks G; Kosiuk J; Arya A; Sommer P; Husser D; Rolf S; Richter S; Piorkowski C; Gaspar T; Lip GY; Bollmann A
    Circ Arrhythm Electrophysiol; 2013 Oct; 6(5):868-74. PubMed ID: 24047706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.